Omeros Corporation (OMER)

Market Cap	471.84M
Revenue (ttm)	n/a
Net Income (ttm)	46.73M
Shares Out	62.83M
EPS (ttm)	0.75
PE Ratio	9.88
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	184,057
Open	7.45
Previous Close	7.41
Day's Range	7.38 - 7.80
52-Week Range	1.74 - 7.80
Beta	1.10
Analysts	Hold
Price Target	3.00 (-59.89%)
Earnings Date	May 9, 2023

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2009
• Employees: 196
• Stock Exchange: NASDAQ
• Ticker Symbol: OMER

Analyst Forecast

According to 3 analysts, the average rating for OMER stock is "Hold." The 12-month stock price forecast is $3.0, which is a decrease of -59.89% from the latest price.

Price Target

$3.0

(-59.89% downside)

Analyst Consensus: Hold